Call Us Now

+91 9606900005 / 04

For Enquiry

legacyiasacademy@gmail.com

Costly HPV Vaccine Needs To Be Part of National Immunisation Programme

Overview

  • Cervical cancer, caused by the Human Papillomavirus (HPV), is among the leading causes of cancer in Indian women.
  • HPV is responsible for 99.7% of cervical cancers globally.
  • The HPV vaccine is highly effective, preventing over 90% of HPV-related cancers.

Relevance : GS 2(Health , Governance)

Current Situation in India

  • The HPV vaccine is available only via private practitioners, though NTAGI has recommended its inclusion in the national immunisation programme.
  • Some states, such as Punjab and Sikkim, have incorporated the vaccine into their immunisation schedules.
  • Recommended: Routine vaccination for girls at 9 years and a catch-up for those aged 9–14.

Benefits of the HPV Vaccine

  • Prevents cervical, vaginal, vulvar, anal, penile, and throat cancers caused by HPV.
  • Effective for both genders, offering protection against genital warts and HPV-related cancers.
  • Safe for immunocompromised individuals, including those with HIV.
  • Vaccines approved in India:
    • Gardasil: Quadrivalent (HPV-6, 11, 16, 18)
    • Cervarix: Bivalent
    • Cervavac: India-made, targets HPV-16 and 18.

Statistics on Cervical Cancer in India

  • 3rd most common cancer among women.
  • Accounts for 18.3% of all cancer cases and 9.1% of cancer deaths in women (GLOBOCAN 2020).
  • High prevalence in areas like Arunachal Pradesh (Papumpare district).

Challenges

  • Cost:
    • Gardasil 9: ₹10,850/dose.
    • Gardasil 4: ₹2,000–₹4,000/dose.
    • Cervavac: ₹2,000/dose.
  • Awareness: Limited understanding of its importance.
  • Cultural Factors: Stigma around reproductive health impacts acceptance.

Recommendations

  • Universal inclusion of the HPV vaccine in the national immunisation programme.
  • Promote awareness campaigns to address cultural and knowledge gaps.
  • Encourage vaccination for all genders to broaden HPV prevention.
  • Focus on vaccinating individuals before exposure (ideally 926 years).

Call to Action

The inclusion of the HPV vaccine in India’s immunisation programme would be a significant step toward reducing the cervical cancer burden. However, affordability, awareness, and systemic challenges must be addressed to achieve this goal.


January 2025
MTWTFSS
 12345
6789101112
13141516171819
20212223242526
2728293031 
Categories